quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant (ICC Vaccine) / Novavax - LARVOL DELTA

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (clinicaltrials.gov) - P3 | N=9320 | Active, not recruiting | Sponsor: Novavax | Trial completion date: Feb 2026 ➔ Sep 2026 | Trial primary completion date: May 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (clinicaltrials.gov) - P3 | N=9320 | Active, not recruiting | Sponsor: Novavax | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Lot Consistency Study of COVID-19 and Influenza Combination Vaccine (clinicaltrials.gov) - P2/3 | N=0 | Withdrawn | Sponsor: Novavax | N=1925 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Lot Consistency Study of COVID-19 and Influenza Combination Vaccine (clinicaltrials.gov) - P2/3 | N=1925 | Not yet recruiting | Sponsor: Novavax | Trial completion date: May 2025 ➔ May 2026 | Initiation date: Nov 2024 ➔ Feb 2025 | Trial primary completion date: Nov 2024 ➔ Nov 2025

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (clinicaltrials.gov) - P3 | N=9320 | Not yet recruiting | Sponsor: Novavax | Trial completion date: Apr 2025 ➔ Feb 2026

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (clinicaltrials.gov) - P3 | N=7950 | Not yet recruiting | Sponsor: Novavax | Phase classification: P2/3 ➔ P3 | N=4000 ➔ 7950

Enrollment change • Phase classification • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Phase 3 Lot Consistency Study of COVID-19 and Influenza Combination Vaccine (clinicaltrials.gov) - P2/3 | N=1650 | Not yet recruiting | Sponsor: Novavax

New P2/3 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (clinicaltrials.gov) - P2 | N=1579 | Completed | Sponsor: Novavax | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Phase 3 Study of the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (clinicaltrials.gov) - P2/3 | N=4000 | Not yet recruiting | Sponsor: Novavax

New P2/3 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (clinicaltrials.gov) - P2 | N=1579 | Active, not recruiting | Sponsor: Novavax | Recruiting ➔ Active, not recruiting | N=2300 ➔ 1579 | Trial completion date: Jul 2023 ➔ Dec 2023

Enrollment change • Enrollment closed • Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (clinicaltrials.gov) - P2 | N=2300 | Recruiting | Sponsor: Novavax | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (clinicaltrials.gov) - P2 | N=2300 | Not yet recruiting | Sponsor: Novavax

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine (clinicaltrials.gov) - P1/2 | N=642 | Completed | Sponsor: Novavax | Active, not recruiting ➔ Completed | Trial primary completion date: Apr 2022 ➔ Dec 2021

Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases